Claims
- 1. A condensed thiophene compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: ##STR44## wherein the ring S is selected from the group consisting of the following fused thiophenes: ##STR45## wherein R.sup.1 represents a hydrogen atom, a halogen atom, an alkyl group, an acyl group or a hydroxyalkyl group;
- R.sup.2 represents a hydrogen atom, an alkyl group, an acyl group, a carbamoyl group, a substituted carbamoyl group, an aryl group or an arylalkyl group;
- G represents a --CH.sub.2 -- group, a --CH(OR.sup.3)-- group, a --CO-- group or a --S(O).sub.t -- group; wherein R.sup.3 represents a hydrogen atom, an alkyl group or an acyl group and t is 0, 1, or 2;
- Q represents a straight alkylene group or a branched chain alkylene group;
- T represents a tertiary amino group;
- D represents a --CH.sub.2 group or a --S(O).sub.u -- group; wherein u is 0, 1 or 2;
- either (i) A is absent and B represents a carbonyl group or a thiocarbonyl group, or (ii) both A and B are absent;
- when A is absent and B is a carbonyl group or a thiocarbonyl group, m is 0 and n is 0, 1 or 2; when both A and B are absent, m is 0 and n is 0 or an integer of 1 to 4.
- 2. The compound of claim 1 selected from the group consisting of:
- 2-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one, or a pharmaceutically acceptable salt thereof.
- 3. The compound of claim 1 selected from the group consisting of:
- 2-(2-(4-(6-fluorobenzo(b)furan-3-yl)piperidin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 2-(2-(4-(5-methylbenzo(b)furan-3-yl)piperidin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 2-(2-(4-(6-fluorobenzo(b)furan-3-yl)piperazin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 2-(2-(4-(4-methylbenzo(b)furan-3-yl)piperazin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 2-(2-(4-(6-methylbenzo(b)furan-3-yl)piperazin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 2-(2-(4-(6-methylbenzo(b)thiophen-3-yl)piperazin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 2-(2-(4-(6-fluorobenzo(b)thiophen-3-yl)piperidin-1-yl)ethyl)-4,6,7,8-tetrahydro-5H-thieno�3,2-b!azepin-5-one,
- 2-(2-(4-(6-fluorobenzo(b)thiophen-3-yl)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-8H-thieno�2,3-c!azepin-8-one,
- 2-(2-(4-(6-fluorobenzo(b)furan-3-yl)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-8H-thieon�2,3 -c!azepin-8 -one,
- 2-(2-(4-(5-methylbenzo(b)furan-3-yl)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-8H-thieno�2,3-c!azepin-8-one,
- 2-(2-(4-(6-methylbenzo(b)furan-3-yl)piperidin-1-yl)ethyl)-4,5,6,7-tetrahydro-8H-thieno�2,3-c!azepin-8-one
- or a pharmaceutically acceptable salt thereof.
- 4. A condensed thiophene compound of the formula: ##STR46## wherein X is hydroxyl, halogen, methanesulfonyloxy or p-toluenesulfonyloxy, and other symbols are as defined in claim 1.
- 5. A pharmaceutical composition comprising a compound of claim 1 and pharmaceutical additives.
- 6. An antipsychotic drug containing a compound of claim 1 as an effective ingredient.
- 7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein T is a tertiary amino of -N(Rb)(Rc), wherein Rb and Rc are the same or different and each is an alkyl group, or Rb and Rc together with the adjacent nitrogen atom form a cyclic amino group represented by the following formulae: ##STR47## wherein q is an integer of 1 to 4; Z is methylene or N-R.sup.5, wherein R.sup.5 is selected from the group consisting of an aryl group, a diarylalkyl group, a heteroaryl group and a heteroarylalkyl group; V is selected from the group consisting of a hydrogen atom, a hydroxyl group, a heteroaryl group, a heteroarylalkyl group and a bisarylmethylene group and the number of V is 1 to 4; the cyclic amino group of formula (1) may contain a carbonyl group in the cycle and may be condensed with an aryl group or a heteroaryl group; and Am of formula (2) may contain an amido bond in the cycle and may contain an oxygen atom, a sulfur atom, a carbonyl group and/or N-R.sup.6 in the ring, wherein R.sup.6 is a hydrogen atom, an alkyl group or a phenyl group.
Priority Claims (2)
Number |
Date |
Country |
Kind |
HEI3-359547 |
Dec 1991 |
JPX |
|
HEI4-309388 |
Oct 1992 |
JPX |
|
Parent Case Info
This is a divisional of application Ser. No. 08/272,320 filed Jul. 8, 1994 now U.S. Pat. No. 5,532,240, which is a continuation-in-part of prior application Ser. No. 08/107,564 filed Aug. 18, 1993 (abandoned), which is a continuation-in-part of PCT/JP92/0695 filed Dec. 24, 1992.
US Referenced Citations (10)
Foreign Referenced Citations (5)
Number |
Date |
Country |
A 58341 |
Aug 1982 |
EPX |
A 150034 |
Jul 1985 |
EPX |
A0465254 |
Jan 1992 |
EPX |
B46-39350 |
Nov 1971 |
JPX |
A48-57994 |
Aug 1973 |
JPX |
Non-Patent Literature Citations (5)
Entry |
Chemical Abstracts, vol. 55, col. 23488 (1961). |
Chemical Abstracts, vol. 59, col. 3862 (1963). |
Chemical Abstracts, vol. 64, col. 586 (1966). |
Chemical Abstracts, vol. 69, 18565x (1968). |
J. Heterocyclic Chem., vol. 13, pp. 1347-1349 (1976) (with English Summary). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
272320 |
Jul 1994 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
107564 |
Aug 1993 |
|